New U.S. Patents Granted for RegenLab

LE-MONT-SUR LAUSANNE, Switzerland, May 21, 2019 /PRNewswire/ -- Mr. Antoine Turzi, inventor, Regen Lab SA and RegenLab USA LLC are delighted to announce that the United States Patent and Trademark Office (USPTO) has issued two new U.S. patents covering its Thrombin Serum (TS), Platelet Rich Plasma (PRP) and Hyaluronic Acid (HA) technologies:

i) Systems/methods for the preparation of PRP and HA in a single "all in one" device - the CELLULAR MATRIX(TM) technology* with tubes containing HA, a thixotropic gel and an anticoagulant: U.S. Patent No. 10,272,139 and

ii) Systems for the preparation of thrombin serum and biological glue, in particular tubes containing a thixotropic gel: U.S. Patent No. 10,226,516.

These new patents represent a recognition by the USPTO of RegenLab's innovation, technology and efficiency. This is great news for RegenLab, its employees and partners, and justifies RegenLab's investment in R&D and enforcement of its intellectual property rights.

This brings a total of 10 (ten) U.S. granted patents on these technologies, expanding RegenLab's patent portfolio along with patents also recently granted in other jurisdictions:

i) Methods for the preparation of PRP by centrifuging tubes with a (polymeric) thixotropic gel (+ anticoagulant) and removing Platelet Poor Plasma (PPP), optionally combined with a cell extract or coagulation activator: US10,092,598

ii) Methods for the preparation of PRP by centrifuging tubes with only a thixotropic gel and anticoagulant, optionally combined with e.g. a coagulation activator, a cell extract, cream, filler, hydrogel, vitamin, antalgic, analgesic or HA: US10,080,770

iii) Systems for the preparation of PRP and Bone Marrow Concentrate (BMC), in particular tubes containing a thixotropic gel and anticoagulant: US10,064,894

iv) Systems/methods combining PRP and HA in two separate devices: US10,052,349

v) Systems/methods for the preparation of PRP, in particular tubes containing a thixotropic gel and sodium citrate as anticoagulant: US9,833,478

vi) Composition comprising HA, anticoagulant and thixotropic gel, tube/container containing such composition, combination with coagulation activator or cell extract: US9,517,255

vii) Methods for the preparation of HA and PRP in a single device, in particular centrifuging tubes containing HA and optionally a gel and anticoagulant, optionally combined with e.g. a coagulation activator or cell extract: US8,945,537

viii) Specific PRP compositions, tubes containing specific thixotropic gels and anticoagulants, combination with cell extracts, related methods and cell culture methods: US8,529,957.


     PRP* ALONE      
     PRP + CELL Culture                   
       ATS* ALONE + PRP                   
       PRP + HA*                         PRP + CELL Extract



     WO2011/110948                        
     WO2008/023026                        
     WO2011/110948                   
     WO2011/110948            WO2008/023026



     WO2013/061309                        
     WO2011/110948   
       US10226516                                         
     WO2013/061309            WO2011/110948



     WO2016/083549                        
     WO2016/083549   
       AU2013203115B                                      
     WO2016/083549            WO2016/083549



     US10092598      
     US8529957                            
       JP6359495                          
       US10272139                    
       US10092598



     US10080770      
     EP2073862B                           
       Pending EP3403659                  
       US9517255                     
       US10080770



     US10064894      
     CH696752                             
       JP2017149786                       
       US8945537                     
       US9517255



     US9833478                                            
       CN105998067                        
       US10052349                    
       US8529957



     US8529957                                            
       IL252122                           
       EP3184114B                    
       EP2073862B



     EP2073862B                                           
       and CA2915649                      
       EP2544697B1                   
       CH696752



     CH696752                                                                                    
       CA2789533C



     HK1231793                                                                                   
       CN103079577B



     Pending                                                                                     
       JP6076091



     US2018353436                                                                                
       AU2011225828B



     EP3111974 and                                                                               
       IL221133



     EP3395383                                                                                   
       RU2614722


                      
     RU2667964



     JP6076091



     JP6321119



     KR20130067247



     HK1179507



     and Pending



     US16/298,112



     7167/DELNP/2012



     JP2017149786

*PRP : Platelet Rich Plasma

*HA : Hyaluronic Acid

*ATS : Autologous Thrombin Serum
CN105998067 US2018327120 and EP2771241

About RegenLab

RegenLab is a leading innovator of medical devices for the preparation of platelet rich plasma, which it markets under the well-recognized REGENLAB®, REGENKIT® and CELLULAR MATRIX(TM)* brands.

RegenLab remains committed to providing pyrogen-free devices of the highest quality and safety, as well as protecting customers through enforcement of its intellectual property rights.

Additional information about RegenLab and its patents can be found at https://www.regenlab.com/corporate/ patents and https://www.regenlabusa.com.

*Only available for research purposes in the United States (not available for sale)

RegenLab® USA LLC 575 Madison Avenue
Suite 1006 New York, NY 10022-2511 Phone & Fax: 1-800-220-9082
www.regenlabusa.com

Regen Lab SA En Budron B2
CH - 1052 Le Mont-Sur-Lausanne
Switzerland
Tel. +41(0)21 864 01.11
Fax. +41(0)21 864 01.10
www.regenlab.com

Roberta Ruggeri, Tel. +41(0)21 864 01 11

View original content to download multimedia:http://www.prnewswire.com/news-releases/new-us-patents-granted-for-regenlab-300854444.html

SOURCE Regen Lab SA